Leading the Next Revolution in Cancer Treatment

At KeyZell, we are transforming cancer treatment through cutting-edge biotechnology, personalized medicine, and advanced science

An Innovative Drug for a Global Challenge

We developed an innovative artificial intelligence system for precision oncology medicine.

Every year, millions face the devastating diagnosis of cancer, often enduring invasive treatments with significant side effects. At KeyZell, we have developed LZ-167, a groundbreaking drug designed to:

Provide an accesible and scalable solution worldwide.

Preservar células sanas, minimizando efectos adversos.

Ser una solución accesible y escalable en todo el mundo.

Subsidiaries

Click on each point to see the contact information for each location.

"LZ-167 has the potential to redefine the standard of care in oncology."

Dr. Nabil Hajji, Investigator

International Recognition

Colaboradores en prestigiosas Instituciones

Santander X Global Challenge Award

Award in the BME Pre-Market Environment

Cancer: A Global Fight We Cannot Afford to Lose.

19 million new cancer cases annually

80% efficacy for LZ-167 in preclinical studies

Target: 4 international clinical trials starting in 2024

Be part of the transformation in oncology with KeyZell Biotech

Learn more about our groundbreaking innovations and discover opportunities to collaborate, invest, or support our mission